Lipid News

The many faces of lipins

Symeon Siniossoglou
By Symeon Siniossoglou
May 1, 2015

Glycerolipids are known to be key components of biological membranes in the form of phospholipids as well as a storage reservoir of fatty acids in the form of triacylglycerols. While we have recognized this for some time now, we are still discovering the critical enzymes, and aspects of their regulation, involved in the synthesis of these lipids.

One important step in the synthesis of glycerolipids involves the dephosphorylation of phosphatidic acid resulting in the generation of diacylglycerol. This key branching step determines the fate of glycerol backbones and fatty acids in lipid biosynthesis.

Diacylglycerol can be acylated to triacylglycerol that is stored in lipid droplets via the glycerol phosphate pathway, or it can be condensed with cytidine diphosphate-choline or cytidine diphosphate ethanolamine for the synthesis of the membrane phospholipids phosphatidylethanolamine and phosphatidylcholine (the Kennedy pathway). Phosphatidic acid also is used for the synthesis of other phospholipids, such as phosphatidylinositol and cardiolipin, by condensation with CDP-diacylglycerol.

In addition to these roles in lipid synthesis, phosphatidic acid and diacylglycerol now are recognized to play important signaling and structural roles in biological membranes. Therefore, regulation of phosphatidic acid dephosphorylation is critical for several aspects of lipid and membrane homeostasis.

Lipins define a class of Mg2+-dependent phosphatidic acid phosphatases collectively known as PAPs. Lipin 1, the founding member of this widely conserved family in eukaryotes, originally was identified as the gene mutated in fatty liver dystrophy mice. These mice display a lipodystrophic phenotype characterized by fatty livers and hypertriglyceridemia.

The demonstration that lipins are in fact PAP enzymes came later, when PAP was purified from budding yeast and found to be a member of the lipin family. Fungi, nematodes and insect genomes each encode one lipin, while human genomes encode three: lipin 1 (the paralogue that has attracted most attention so far), lipin 2 and lipin 3. Research in a multitude of model organisms has advanced our knowledge over the past 10 years, uncovering many surprising aspects of lipin biology and raising intriguing questions regarding their function and regulation.

LipidNews-Lipins-primary.pngLipid metabolic roles of lipins

Unlike the other enzymes of the triacylglycerol biosynthetic pathway, lipins lack transmembrane domains and exhibit in most cells a primarily soluble distribution. As a consequence, lipin membrane targeting is a key regulatory step in triacylglycerol metabolism.

Lipins are sequestered in the cytosol via hyperphosphorylation via growth/nutrient or cell-cycle-dependent phosphorylation catalysed by several kinases, such as TOR in mammals and Pho85 or Cdc28, among others, in yeast (See Choi, H.S et al 2012 and Choi, H.S et al 2011).

A highly conserved transmembrane phosphatase complex, originally described in yeast, mediates activation of lipins and their association with membranes (See Santos-Rosa, H et al 2005 and Karanasios, E et al 2010).

Recent studies have highlighted additional control of the membrane-bound lipins: Cytosolic pH via electrostatic interaction between phosphatidic acid and lipin 1 and proteasome-mediated degradation of active lipin in yeast cells are important determinants of PAP levels. Such multilevel regulation may allow lipins to modulate phosphatidic acid and diacylglycerol levels on different membranes.

Indeed, in addition to their biosynthetic roles in the endoplasmic reticulum, yeast and mammalian lipins also have roles in mitochondria, lipid droplets, nuclear membrane, vacuoles and the autophagosome.

The physiological consequences of lipin dysfunction are emerging as an area of intense and exciting research.

As alluded to above, lipins are critical for triacylglycerol synthesis in yeasts, plants, worms and flies. Rodent models of lipin 1 deficiency display a lipodystrophic phenotype characterized by significant reduction in fat mass and lack of adipocyte differentiation. It also turns out that lipins are essential for maintenance of nuclear structure and endoplasmic reticulum membrane organization, suggesting that their dysfunction also could affect metabolic homeostasis through structural mechanisms.

Surprisingly, deleterious mutations in lipin 1 do not affect fat distribution in humans but instead cause severe myopathy in the form of rhabdomyolysis. Recently, this has been proposed to result from defective lipin 1-mediated autophagic clearance in muscle. The basis for the different fat pathologies between rodent models and humans remains a critical question to be answered.

Perhaps the most unexpected aspect of lipins is that they have a distinct intranuclear pool in many cell types. For example, lipin 1 can regulate expression of genes encoding fatty-acid metabolic enzymes via physical interactions with components of the transcription machinery. The presence of a nuclear PAP enzyme raises many intriguing questions.

One unresolved issue is whether the localization and function of lipin in the nucleus is linked somehow to its role in modulating lipid metabolism in the cytoplasm. It is also not known whether nuclear PAP affects nuclear membrane biogenesis and nuclear signalling.

Given the emerging roles of the nuclear envelope in gene expression, lipins could control transcription through lipid remodelling at the nuclear membrane. For example, nuclear import of lipin 1 in response to nutrient depletion causes nuclear envelope remodelling, which down-regulates the major lipogenic factor SREBP (short for sterol regulatory element-binding protein) through unknown mechanisms.

While we’ve learned a lot about lipins, it is clear that there are many remaining questions. Addressing these questions will be vital to understanding the mechanisms that underlie the emerging roles of lipins in cellular and organismal homeostasis.

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Symeon Siniossoglou
Symeon Siniossoglou

Symeon Siniossoglou is a principal investigator at the Cambridge Institute for Medical Research at the University of Cambridge.

Related articles

Targeting cardiolipin modification in a genetic disorder
Arianna F. Anzmann, Olivia Sniezek & Hilary Vernon
At the interface
Lina M. Obeid & Michael J. Pulkoski-Gross
Unexpected roles of lipid kinases
Kaoru Goto & Toshiaki Tanaka
Back to the (poly)basics
Salome Boroda & Thurl Harris

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Simple trick could improve accuracy of plant genetics research

Simple trick could improve accuracy of plant genetics research

June 16, 2024

Researchers at North Carolina State University have found that a technique used to study gene activity in other organisms can also be used to make studies in plants more accurate.

Scientists track 'doubling' in origin of cancer cells

Scientists track 'doubling' in origin of cancer cells

June 15, 2024

Researchers at Johns Hopkins say they have charted a molecular pathway that can lure cells down a hazardous path of duplicating their genome too many times.

From the journals: JBC
Journal News

From the journals: JBC

June 14, 2024

Ribosomal RNA, R-loops and the RNA exosome. Using an old drug to treat a new skin disease, Sugar-binding immune receptors. Read about recent papers on these topics.

New gene new strides in gangliosidosis
Journal News

New gene new strides in gangliosidosis

June 11, 2024

A gene that decreases disease progression in mice provides a new direction for human therapy.

Brushing with bacteria: The debate over a GMO tooth microbe

Brushing with bacteria: The debate over a GMO tooth microbe

June 9, 2024

One startup has said a genetically modified microbe could prevent cavities. Experts, though, have safety concerns.

Newly discovered genetic variant clarifies why Parkinson’s develops

Newly discovered genetic variant clarifies why Parkinson’s develops

June 8, 2024

Researchers at the University of Florida have found that the mutation called RAB32 Ser71Arg both causes the condition and could show how to halt it.